Life Scientist > Lab Technology

Pharmaxis signs first Aridol distributor

18 January, 2006 by Helen Schuller

Sydney-based drug developer Pharmaxis (ASX:PXS, Nasdaq:PXSL) has signed a European distribution agreement for its first product, Aridol.


Skladnev steps down as Polartechnics CEO

17 January, 2006 by Ruth Beran

Following a board stoush last year and calls by shareholders at the company's AGM for a change in management, Polartechnics (ASX:PLT) CEO Victor Skladnev was yesterday replaced by Ben Dillon.


Australian researchers awarded $1m Pfizer fellowships

13 January, 2006 by Ruth Beran

Dr Stephen Nutt, based at the Walter and Eliza Hall Institute, and Dr Anthony Hannan, at the Howard Florey Institute, have each been awarded five-year grants of AUD$1 million under the Pfizer Australia Research Fellowship scheme.


C3 clarifies TGA intention to reject ReCell

12 January, 2006 by Ruth Beran

Tissue engineering specialist Clinical Cell Culture (ASX:CCE, C3) has clarified aspects of its application for approval to market its ReCell product in Australia, following a decision by the Therapeutic Goods Administration (TGA) in December to reject approval for the product.


Novogen's US subsidiary postpones Nasdaq IPO

12 January, 2006 by Ruth Beran

Sydney-based biopharma Novogen's (ASX:NRT, Nasdaq:NVGN) US subsidiary, Glycotex, is to postpone its IPO on the Nasdaq national market.


NSW forum to explore research ethics review

11 January, 2006 by Staff Writers

The NSW government's health department is to run a series of forums to explain an ethical review of multi-centre research, including progress towards a model of single ethical and scientific review.


Leroy Hood to consult for LabCorp

11 January, 2006 by Staff Writers

Systems biology guru Dr Leroy Hood has entered into a strategic consulting relationship with US molecular testing equipment specialist LabCorp.


Biotech performance was tale of two halves in 2005: Intersuisse

11 January, 2006 by Ruth Beran

Australian biotech stocks underperformed both the All Ordinaries and the Nasdaq Biotech Index in 2005, but the second half of the year was brighter with stocks gaining 23.2 per cent, according to the Intersuisse Biotechnology Index.


Australian experts disappointed by Hwang findings

10 January, 2006 by Staff Writers

Australian stem cell research experts have spoken out, in a series of statements, of their disappointment in the wake of findings by an independent review panel that a team led by South Korean scientist Hwang Woo-suk fabricated research on potentially groundbreaking papers on embryonic stem cells.


A way around a problem

21 December, 2005 by Iain Scott

Biotechnology has provided a solution to the problem of how to get science to the market without compromising research, writes editor-in-chief Iain Scott.


Facing up to commercial reality

21 December, 2005 by Ruth Beran

The research community is becoming more sophisticated in the way they approach intellectual property and industry partnerships. Ruth Beran looks at how technology transfer has changed, where it is going and the challenges it faces.


INTERVIEW: Sir Gus's big picture view

15 December, 2005 by Ruth Beran

Ruth Beran asked Sir Gustav Nossal about Australia's latest institute -- which just happens to bear his name.


Glaxo is using delaying tactics: Biota CEO

14 December, 2005 by Ruth Beran

The CEO of Melbourne company Biota Holdings (ASX:BTA), Peter Cook, believes GlaxoSmithKline is using delaying tactics in the current court case before the Victorian courts, in which Biota is suing GSK for up to AUD$430 million.


Alchemia raises $5m in share purchase plan

14 December, 2005 by Helen Schuller

Brisbane biopharma Alchemia (ASX:ACL) has successfully raised AUD$5 million, closing its share purchase plan heavily oversubscribed. Earlier this month the company raised $14.6 million through a share placement.


BrainZ lists at premium

14 December, 2005 by Helen Schuller

Auckland-based BrainZ (ASX:BZI), which develops monitors for the detection of brain injury, listed on the ASX today at AUD$0.54, four cents above its issue price of $0.50.


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd